Evidence map›Paper›PMID 41465396›Full record

ArticleInternational journal of molecular sciences2025

Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer.

Dan Corneliu Jinga, Georgiana Duta-Cornescu, Danut Cimponeriu, Eirini Papadopoulou, Angeliki Meintani, George Tsaousis, Amalia Chirnogea, Irina Bucatariu, Polixenia-Georgeta Iorga, Diana Chetroiu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Dan Corneliu JingaNeolife Medical Center, 013975 Bucharest, Romania.
Georgiana Duta-CornescuDepartment of Applied Genetic and Biotechnology, Faculty of Biology, University of Bucharest, 050095 Bucharest, Romania.ORCID 0000-0002-0816-3715
Danut CimponeriuDepartment of Applied Genetic and Biotechnology, Faculty of Biology, University of Bucharest, 050095 Bucharest, Romania.ORCID 0000-0002-2508-0305
Eirini PapadopoulouGenekor Medical S.A., 153044 Athens, Greece.
Angeliki MeintaniGenekor Medical S.A., 153044 Athens, Greece.
George TsaousisGenekor Medical S.A., 153044 Athens, Greece.ORCID 0000-0002-8975-8779
Amalia ChirnogeaGenekor Medical SRL, 014145 Bucharest, Romania.
Irina BucatariuGenekor Medical SRL, 014145 Bucharest, Romania.
Polixenia-Georgeta IorgaGeneral Oncology Unit, University Emergency Hospital Bucharest, 050098 Bucharest, Romania.ORCID 0009-0006-5448-4284
Diana ChetroiuGeneral Oncology Unit, University Emergency Hospital Bucharest, 050098 Bucharest, Romania.
Sorin-Cornel HosuGeneral Oncology Unit, Alba Iulia Country Hospital Emergency, 510007 Alba Iulia, Romania.
Amalia Hogea-ZahGeneral Oncology Unit, Satu Mare Country Emergency Hospital, 440192 Satu Mare, Romania.
Mircea-Dragos MedianGeneral Oncology Unit, Filantropia Clinical Hospital, 011171 Bucharest, Romania.ORCID 0000-0001-5842-1850
Bogdan DianaDonna Medical Center, 021755 Bucharest, Romania.
Dana-Lucia StănculeanuInstitute of Oncology Prof. Dr. Alexandru Trestioreanu, 022328 Bucharest, Romania.ORCID 0000-0003-3930-2543
Raluca MihailaInstitute of Oncology Prof. Dr. Alexandru Trestioreanu, 022328 Bucharest, Romania.ORCID 0000-0003-1551-7654
Dana-Sonia NagyOncohelp Oncology Center, 300239 Timisoara, Romania.
Pompilia-Elena MotatuGeneral Oncology Unit, Ploiești Municipal Hospital, 100337 Ploiesti, Romania.
Turcanu EugeniuNeolife Medical Center, 700503 Iasi, Romania.
Elena-Octaviana CristeaGeneral Oncology Unit, Elias University Emergency Hospital, 011461 Bucharest, Romania.
Ion-Cristian IaciuGeneral Oncology Unit, Elias University Emergency Hospital, 011461 Bucharest, Romania.
Paul KubelacInstitute of Oncology Prof. Dr. I. Chiricută, 400015 Cluj-Napoca, Romania.
Andreea TruicanGenekor Medical SRL, 014145 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homologous recombination deficiency (HRD) is a clinically relevant biomarker that predicts sensitivity to PARP inhibitors and enables personalized cancer therapy. Validated local HRD testing solutions are essential to ensure timely and equitable access, ultimately improving treatment outcomes. We evaluated a shallow whole-genome sequencing (sWGS) approach for genomic instability (GI) assessment combined with a 52-gene targeted panel in ovarian cancer. Validation used reference materials and 24 archival samples with prior HRD characterization, comparing performance with the Myriad myChoice

Indexed as

Homologous RecombinationOvarian NeoplasmsWhole Genome SequencingAdultAgedAged, 80 and overBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinFemaleGenomic InstabilityHumansMiddle AgedPoly(ADP-ribose) Polymerase InhibitorsProspective StudiesBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase Inhibitorsgenomic instabilityhomologous recombination deficiencyovarian cancerPARP inhibitorssWGS

Identifiers

PMID41465396
PMCPMC12732861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.